Adsorbents for oral administration

Patent metadata

Field	Value
Publication number	US-9682046-B2
Application number	US-201214349512-A
Country	US
Kind code	B2
Filing date	Oct 5, 2012
Priority date	Oct 7, 2011
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

The present invention aims to provide an adsorbent for oral administration comprising ACF that has high adsorption or removal performance by adsorbing or removing toxic substances in the living body greatly and rapidly. The present invention is an adsorbent for oral administration comprising activated carbon fibers for treating or preventing kidney diseases or dialysis complications.

First claim

The invention claimed is:

1. A method for adsorbing a uremic toxin comprising oral administration of activated carbon fiber to a subject in need thereof;
wherein when the activated carbon fiber is a rayon-based activated carbon fiber, the diameter of the rayon-based activated carbon fiber is at least 9 μm.

2. The method according to claim 1 , wherein the activated carbon fibers have a micropore volume of 0.1 to 2.0 mL/g.

3. The method according to claim 1 , wherein the activated carbon fibers have a fiber length of 15 μm or more and a micropore volume of 0.5 to 1.0 mL/g.

4. The method according to claim 1 whereby kidney diseases or dialysis complications are treated or prevented.

5. The method according to claim 1 , wherein the adsorbent is administered at a daily dose of 1 to 3000 mg.

6. A method for adsorbing a uremic toxin comprising oral administration of activated carbon fiber to a subject in need thereof; wherein the activated carbon fiber has a cross-sectional diameter of the fiber of 5 to 50 μm, a fiber length of 15 μm or more, a specific surface area as determined by BET method of 1400 to 2700 m 2 /g, a total pore volume of 0.8 to 1.8 mL/g, and a micropore volume of 0.5 to 1.0 mL/g; wherein when the activated fiber is a rayon-based activated carbon fiber, the diameter of the rayon-based activated carbon fiber is at least 9 μm.

Assignees

• Teijin Pharma Ltd

Inventors

• Nishiwaki Yasumi
• Murakami Takashi
• Eto Nobuaki
• Imaizumi Keiichiro
• Ohtaki Akihito
• Shimazaki Kenji

Classifications

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• A61P39/02

  Antidotes · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P13/12

  of the kidneys · CPC title